Electroretinogram Market Size and Trends
The electroretinogram market size was exhibited at USD 696.15 million in 2024 and is projected to hit around USD 1518.31 million by 2034, growing at a CAGR of 8.11% during the forecast period 2024 to 2034.
The electroretinogram (ERG) market represents a critical domain within ophthalmic diagnostics, enabling the assessment of retinal function through the measurement of electrical responses to light stimuli. ERG is an invaluable clinical and research tool for detecting inherited retinal disorders, monitoring drug toxicity, evaluating retinal damage in systemic diseases, and supporting emerging gene and cell therapies targeting retinal conditions. As the global burden of vision-related diseases escalates—driven by aging populations, diabetes prevalence, and genetic disorders—the demand for advanced, non-invasive diagnostic modalities like ERG continues to expand.
At its core, electroretinography measures the summed electrical activity of various retinal cell types, including photoreceptors, bipolar cells, and ganglion cells, offering a comprehensive view of retinal integrity. Traditionally used in specialty eye clinics and research institutions, ERG is now experiencing broader adoption in general ophthalmology and clinical trials for retinal gene therapies, particularly for conditions like retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease.
The market’s growth is strongly supported by technological advancements, including the miniaturization of ERG devices, the integration of wireless data transmission, and improved signal resolution for high-definition waveform analysis. Leading manufacturers are developing portable, user-friendly devices that are enhancing access in both developed and emerging healthcare systems. Furthermore, regulatory support from agencies like the FDA and EMA for ERG as a validated endpoint in clinical trials is encouraging wider clinical use.
In the context of research, ERG plays a vital role in preclinical drug development and translational studies, especially in the ophthalmology and neurology domains. Pharmaceutical companies and academic institutions increasingly rely on ERG measurements for in vivo assessments of retinal drug efficacy and safety, boosting the relevance of the modality in laboratory settings. With increasing investments in vision science and retinal gene therapy pipelines, the ERG market is positioned for sustained growth over the next decade.
Rising Demand for Retinal Disease Diagnostics: The increase in age-related macular degeneration (AMD), diabetic retinopathy, and inherited retinal diseases is driving the adoption of ERG systems.
Miniaturization and Portability of ERG Devices: Development of handheld and wireless ERG units is improving point-of-care access and enabling decentralized diagnostics.
Integration of ERG in Gene Therapy Trials: Regulatory bodies are endorsing ERG as a clinical endpoint in ophthalmic gene and cell therapy development programs.
AI-Enhanced ERG Analysis: Artificial intelligence and machine learning are being applied to automate waveform interpretation and improve diagnostic accuracy.
Expansion into Pediatric and Geriatric Applications: ERG is gaining acceptance in neonatal screening and geriatric assessments of retinal function.
Increased Investment in Ophthalmic Research: Universities and pharma companies are using ERG systems in preclinical and early-phase retinal drug trials.
Software and Data Analytics Integration: Cloud-enabled ERG platforms now offer remote access to reports and real-time collaboration for teleophthalmology.
Standardization of ERG Protocols: Growing adoption of ISCEV standards ensures consistency and reliability across global ERG testing sites.
| Report Coverage | Details |
| Market Size in 2025 | USD 752.61 Million |
| Market Size by 2034 | USD 1518.31 Million |
| Growth Rate From 2024 to 2034 | CAGR of 8.11% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Type, Product, Application |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | LKC Technologies, Inc.; Diagnosys LLC; Electro-Diagnostic Imaging, Inc.; Diopsys, Inc.; Metrovision; Roland-consult; CSO Italia |
Increasing Prevalence of Retinal and Neurodegenerative Disorders
One of the key factors driving the electroretinogram market is the growing global burden of retinal diseases, many of which are progressive and irreversible if not diagnosed early. Conditions such as retinitis pigmentosa, diabetic retinopathy, macular dystrophies, and glaucoma often cause structural and functional retinal damage that is detectable before visual symptoms arise. ERG plays a critical role in the early detection of these disorders by providing functional insights that structural imaging modalities like OCT cannot capture alone.
Additionally, systemic conditions such as Parkinson’s and Alzheimer’s disease, which are linked to retinal abnormalities, are increasingly studied using ERG as a non-invasive biomarker of neurological decline. In diabetic populations, ERG helps assess subclinical retinal dysfunction even in the absence of retinopathy, allowing for proactive disease management. With aging demographics, growing diabetes incidence, and enhanced access to specialty care, the need for advanced functional testing tools like ERG is rapidly expanding.
High Cost and Limited Reimbursement of ERG Testing
Despite its diagnostic utility, the adoption of ERG devices is sometimes hindered by high acquisition and operational costs, particularly in smaller clinics and resource-limited settings. Advanced ERG systems with multifocal and pattern stimulation capabilities require significant capital investment, along with trained personnel to perform tests and interpret results. This creates a financial barrier for facilities looking to incorporate ERG into routine diagnostic services.
Furthermore, inconsistent reimbursement policies—especially in countries where ERG testing is not standardized within insurance coverage—pose additional constraints. In the U.S., while ERG is covered under certain conditions, its use must be carefully documented and justified. Lack of awareness about billing codes and inconsistent payer support can discourage widespread deployment of the technology. These challenges, unless addressed by policy harmonization and cost reduction strategies, may limit market penetration in economically constrained environments.
Integration of ERG in Clinical Trials and Ophthalmic Drug Development
The growing pipeline of therapies for inherited and acquired retinal diseases presents a major opportunity for the ERG market, particularly in the clinical trials segment. As new gene, RNA-based, and cell therapies target specific retinal cell populations, ERG has become a valuable endpoint for assessing functional efficacy in both preclinical and clinical phases. Regulatory agencies now recognize ERG as a quantifiable, objective measure of photoreceptor and inner retinal activity, making it integral to evidence generation.
This is particularly relevant for rare genetic disorders where structural imaging may not sufficiently capture therapeutic impact. CROs, pharma companies, and academic trial sites are investing in portable ERG systems to enable multi-center testing under standardized protocols. Companies that offer cloud-based ERG platforms with centralized data management and ISCEV compliance are well-positioned to support global clinical trial expansion. The market stands to benefit from the broader inclusion of ERG endpoints in trials sponsored by biotech firms focused on ophthalmology.
Full-field flash ERG (ffERG) is the most widely used ERG type and currently dominates the market due to its ability to provide a comprehensive overview of generalized retinal function. ffERG is essential for evaluating widespread retinal diseases such as retinitis pigmentosa, congenital stationary night blindness, and rod-cone dystrophies. It is also a standard tool for detecting retinal toxicity from systemic drugs like hydroxychloroquine. Hospitals, vision centers, and research institutions favor ffERG for its diagnostic reliability and versatility, especially in baseline testing and longitudinal disease monitoring.
Multifocal ERG (mfERG) is the fastest-growing segment, driven by its precision in mapping localized retinal function, particularly in the macular region. mfERG is indispensable in the diagnosis of central retinal disorders such as macular degeneration, Stargardt disease, and pattern dystrophies. Its ability to generate a topographic map of retinal responses allows clinicians to detect functional changes that may not yet be apparent in imaging. The rising use of mfERG in gene therapy trials and visual performance research is expanding its clinical and academic footprint.
The clinical diagnostic segment accounted for the largest revenue share of 70.0% in 2024 and is projected to witness the fastest CAGR over the forecast period, as ERG continues to be a critical tool in diagnosing a variety of retinal pathologies. Ophthalmologists routinely employ ERG for functional evaluation when structural imaging is inconclusive or for confirming the extent of disease involvement. With increasing prevalence of retinal degenerative diseases, especially in geriatric and diabetic populations, clinical ERG usage is growing within hospitals, private eye care centers, and retina specialty clinics. Additionally, screening for drug-induced retinopathy is making ERG more mainstream in general medicine.
Research is the fastest-growing application, fueled by surging investments in vision science, neuro-ophthalmology, and regenerative medicine. ERG plays an integral role in assessing visual function in preclinical models and human subjects during clinical trials. Academic institutions and pharmaceutical companies are incorporating ERG endpoints into experimental protocols for gene therapies, stem cell interventions, and pharmacologic agents. The rise in government and private funding for ophthalmic innovation is accelerating demand for high-resolution, customizable ERG systems tailored to research use.
Tabletop ERG devices dominate the product landscape, primarily due to their established use in hospitals, specialty ophthalmology centers, and academic research labs. These devices offer high signal resolution, greater electrode control, and multiple test protocols, supporting a broad range of clinical and research applications. Tabletop models are often integrated with dark-adaptation rooms and are preferred in institutions managing complex retinal disease profiles. Their robust build and superior accuracy make them indispensable for long-term diagnostics and therapy evaluation.
Handheld ERG devices are the fastest-growing product category, gaining popularity due to their portability, ease of use, and ability to facilitate ERG testing in outpatient settings, pediatric clinics, and even home-care scenarios. Companies like LKC Technologies and Diopsys are pioneering compact, battery-operated models that deliver reliable test results with minimal patient preparation. Handheld ERGs are enabling decentralized screening programs in rural areas and mobile ophthalmology units, creating new access points for early detection of retinal diseases.
North America leads the global ERG market, driven by advanced healthcare infrastructure, high awareness of retinal disorders, and early adoption of ophthalmic technologies. The U.S. is home to major manufacturers, leading eye hospitals, and robust research programs in ophthalmology, making it the epicenter of innovation and clinical application. Initiatives like the National Eye Institute’s (NEI) support for rare retinal disease research and the integration of ERG in clinical trials reinforce its use in clinical and academic domains. Additionally, favorable reimbursement policies for electrophysiological testing support greater use of ERG in routine and specialized care.
Asia Pacific is the fastest-growing region, spurred by rising awareness of preventable blindness, expansion of ophthalmology services, and increased screening programs in countries like China, India, Japan, and South Korea. The growing diabetic population is also contributing to the demand for early detection of diabetic retinopathy through ERG screening. Government healthcare initiatives and public-private partnerships focused on retinal health are enhancing infrastructure and funding availability. In addition, local manufacturers are entering the market with cost-effective ERG solutions, improving accessibility in tier-2 and tier-3 cities across the region.
January 2025: LKC Technologies launched a wireless, cloud-connected handheld ERG device targeted at mobile ophthalmic practices and pediatric screening.
February 2025: Diagnosys LLC announced FDA clearance for its new mfERG software upgrade, integrating AI-based waveform analysis for improved diagnostic accuracy.
March 2025: Diopsys entered a strategic partnership with an AI startup to develop predictive algorithms for glaucoma progression using PERG waveforms.
April 2025: Roland Consult introduced a hybrid tabletop system that combines ffERG and mfERG capabilities with a touchscreen interface and automated calibration.
April 2025: The University of Michigan began a multi-center study evaluating ERG as a biomarker for early-stage Alzheimer’s disease, underscoring its role beyond ophthalmology.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the electroretinogram market
By Type
By Product
By Application
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers